Message_id,From,Time_stamp,Text
<7292076.1075859391940.JavaMail.evans@thyme>,altcap@rogers.com,2001-12-07 09:20:37,Viral GeneticsVRAL Achieves unprecedented AIDS breakthroughVIRAL GENETICS INC December HIGHLIGHTS Viral Genetics has developed a revolutionary new technology called TNP which based on clinical results to date not only stops but also reverses the progression of HIV infection in people TNP is an extracted naturally occurring biologically active linear protein which when purified and modified greatly stimulates the bodys immune response system Three months after an eight week TNP treatment out of terminally ill AIDS patients in clinical trials show virtually no sign of HIV infection TNP treated patients display virtually no side effects to treatment TNP technology is patented in countries and patent pending in Canada and the US Treatments are far less costly and less cumbersome than currently employed alternatives OVERVIEW Viral Genetics Inc was founded in to develop and commercialize therapeutic and diagnostic systems for the treatment of viral diseases Their primary focus has been on finding a treatment which would stop and reverse the progression of HIV infection in humans After expenditures in excess of M Viral Genetics developed their core technology TNP Thymus Nuclear Protein Since TNPs discovery Viral Genetics has conducted numerous animal studies and three human clinical trials Each human trial consisted of to patients in the late stages of infection TNP was administered by intramuscular injection biweekly over an eight week period Follow up was carried out on all the patients anywhere from to days after treatment The trials revealed the following incredible results with respect to TNPs efficacy and safety HIV viral levels were reduced by even months after treatment Patients experienced minimal side effects during treatment which completely subsided after treatment and remained that way even months after treatment Dramatic reductions occurred even with HIV resistant strains that no Antiviral Drug Cocktail has shown any efficacy with whatsoever Most patients started to regain body weight during and after TNP treatment Viral Genetics is in discussions with a number of world wide governments to commercialize the TNP technology STRUCTURE Listed OTCBB Symbol VRAL Shares Outstanding M Public Float M Warrants none Options none Website wwwviralgeneticscom Recent Price Share Price High Share Price Low For further information please contact Alternative Capital Group 
<17144653.1075859391963.JavaMail.evans@thyme>,altcap@rogers.com,2001-12-07 09:29:56,Viral GeneticsVRAL Achieves unprecedented AIDS breakthroughVIRAL GENETICS INC December HIGHLIGHTS Viral Genetics has developed a revolutionary new technology called TNP which based on clinical results to date not only stops but also reverses the progression of HIV infection in people TNP is an extracted naturally occurring biologically active linear protein which when purified and modified greatly stimulates the bodys immune response system Three months after an eight week TNP treatment out of terminally ill AIDS patients in clinical trials show virtually no sign of HIV infection TNP treated patients display virtually no side effects to treatment TNP technology is patented in countries and patent pending in Canada and the US Treatments are far less costly and less cumbersome than currently employed alternatives OVERVIEW Viral Genetics Inc was founded in to develop and commercialize therapeutic and diagnostic systems for the treatment of viral diseases Their primary focus has been on finding a treatment which would stop and reverse the progression of HIV infection in humans After expenditures in excess of M Viral Genetics developed their core technology TNP Thymus Nuclear Protein Since TNPs discovery Viral Genetics has conducted numerous animal studies and three human clinical trials Each human trial consisted of to patients in the late stages of infection TNP was administered by intra muscular injection biweekly over an eight week period Follow up was carried out on all the patients anywhere from to days after treatment The trials revealed the following incredible results with respect to TNPs efficacy and safety HIV viral levels were reduced by even months after treatment Patients experienced minimal side effects during treatment which completely subsided after treatment and remained that way even months after treatment Dramatic reductions occurred even with HIV resistant strains that no Antiviral Drug Cocktail has shown any efficacy with whatsoever Most patients started to regain body weight during and after TNP treatment Viral Genetics is in discussions with a number of world wide governments to commercialize the TNP technology STRUCTURE Listed OTCBB Symbol VRAL Shares Outstanding M Public Float M Warrants none Options none Website wwwviralgeneticscom Recent Price Share Price High Share Price Low For further information please contact Alternative Capital Group 
<18771147.1075859392011.JavaMail.evans@thyme>,altcap@rogers.com,2001-12-07 10:27:28,VRAL Achieves unprecedented AIDS breakthroughVIRAL GENETICS INC December HIGHLIGHTS Viral Genetics has developed a revolutionary new technology called TNP which based on clinical results to date not only stops but also reverses the progression of HIV infection in people TNP is an extracted naturally occurring biologically active linear protein which when purified and modified greatly stimulates the bodys immune response system Three months after an eight week TNP treatment out of terminally ill AIDS patients in clinical trials show virtually no sign of HIV infection TNP treated patients display virtually no side effects to treatment TNP technology is patented in countries and patent pending in Canada and the US Treatments are far less costly and less cumbersome than currently employed alternatives OVERVIEW Viral Genetics Inc was founded in to develop and commercialize therapeutic and diagnostic systems for the treatment of viral diseases Their primary focus has been on finding a treatment which would stop and reverse the progression of HIV infection in humans After expenditures in excess of M Viral Genetics developed their core technology TNP Thymus Nuclear Protein Since TNPs discovery Viral Genetics has conducted numerous animal studies and three human clinical trials Each human trial consisted of to patients in the late stages of infection TNP was administered by intramuscular injection biweekly over an eight week period Follow up was carried out on all the patients anywhere from to days after treatment The trials revealed the following incredible results with respect to TNPs efficacy and safety HIV viral levels were reduced by even months after treatment Patients experienced minimal side effects during treatment which completely subsided after treatment and remained that way even months after treatment Dramatic reductions occurred even with HIV resistant strains that no Antiviral Drug Cocktail has shown any efficacy with whatsoever Most patients started to regain body weight during and after TNP treatment Viral Genetics is in discussions with a number of world wide governments to commercialize the TNP technology STRUCTURE Listed OTCBB Sy mbol VRAL Shares Outstanding M Public Float M Warrants none Op tions none Website wwwviralgeneticscom Recent Price Share Price High Share Price Low For further information please contact Alternative Capital Group 
